Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

121. Among Adult Cancer Survivors Treated With Anthracycline Chemotherapies, Concurrent Statin Therapy May Reduce Their Decline in Left Ventricular Dysfunction

Among Adult Cancer Survivors Treated With Anthracycline Chemotherapies, Concurrent Statin Therapy May Reduce Their Decline in Left Ventricular Dysfunction "Among Adult Cancer Survivors Treated With Anthracycline Chemotherapies" by Mariah McGaffey < > > > > > Title Author Date of Graduation Spring 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers Rights . Abstract Background: Anthracycline chemotherapies are used (...) to treat a wide variety of malignancies. A study by Von Hoff et al showed that 2.2% of patients previously treated with anthracycline chemotherapy were later diagnosed with heart failure. A more recent study by Smain, et al, showed that 26% of patients receiving higher doses of anthracycline were later diagnosed with heart failure. Statins have been shown to have properties that may allow them to be cardioprotective. Animal research performed by Henninger et al suggests that statin therapy

2016 Pacific University EBM Capstone Project

122. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email (...) Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients

2016 American Heart Association

123. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication Final Update Summary: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication Release Date: November 2016 (...) Recommendation Summary Population Recommendation Grade Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 10% or greater The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (ie, symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1

2016 U.S. Preventive Services Task Force

124. Statin Choice Electronic Decision Aid

Statin Choice Electronic Decision Aid Statin Choice Decision Aid - Site Statin Choice Decision Aid Welcome to the Statin Choice Decision Aid. This tool will help you and your doctor discuss how you might want to reduce your risk for heart attacks. Caution: This application is for use exclusively during the clinical encounter with your clinician (Updated May, 2018) (Updated February 6, 2015) LEGAL CONDITIONS AND TERMS OF USE APPLICABLE TO ALL USERS OF THIS SITE. ANY USE OF THIS SITE CONSTITUTES (...) YOUR AGREEMENT TO THESE TERMS AND CONDITIONS OF USE. © 1998-2019 Mayo Foundation for Medical Education and Research. All rights reserved. Generating Report... Cancel Statin Choice Decision Aid To: CC: Subject:

2016 Washington Health Care Authority

125. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease (PubMed)

Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease Statins are extensively used to treat dyslipidemia, but, because of their low tolerability profile, they are discontinued in a significant proportion of patients. Ezetimibe and nutraceuticals have been introduced as alternative therapies and have proved to be effective and well tolerated. A single-blind, single-center, randomized, prospective (...) the therapeutic goal. No patients experienced important undesirable effects. In conclusion, nutraceuticals alone or in combination with ezetimibe are well tolerated and improve the lipid profile in statin-intolerant patients with coronary heart disease. Further studies are needed to assess long-term effects of nutraceuticals on mortality.Copyright © 2015 Elsevier Inc. All rights reserved.

2015 EvidenceUpdates

126. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk (Full text)

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This phase 3 study evaluated the efficacy and safety of evolocumab plus atorvastatin in Japanese patients with hyperlipidemia or mixed dyslipidemia and high cardiovascular risk. Patients were randomized to atorvastatin 5 (...) between treatment groups. Efficacy and safety for Q2W or QM evolocumab dosing were similar. In conclusion, in high-risk Japanese patients receiving stable statin therapy, evolocumab markedly reduced LDL-C and was well tolerated.Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

2015 EvidenceUpdates PubMed

127. Statins Reduce Mortality After Non-severe but Not After Severe Pneumonia: A Systematic Review and Meta-Analysis. (PubMed)

Statins Reduce Mortality After Non-severe but Not After Severe Pneumonia: A Systematic Review and Meta-Analysis. The objective of this study was to perform a systematic review and meta-analysis of the effects of statins on mortality for patients with non-severe pneumonia or severe pneumonia.PubMed, EMBASE, Cochrane Database of Systematic Reviews, Cochrane central register of controlled trials and Clinicaltrials.gov were searched for the association between statins and non-severe/severe (...) pneumonia. Eligible articles were analyzed in Stata 12.0.The database search yielded a total of 566 potential publications, 24 studies involving 312,309 patients met the eligibility criteria. Pooled unadjusted data showed that statin use was associated with lower mortality after non-severe pneumonia (odds ratio [OR] 0.70, 95% confidence interval [CI], 0.66-0.73), but not severe pneumonia (OR 1.05; 95% CI, 0.86-1.28). However, this protective effect of statins was weakened using adjusted estimates

2015 Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques

128. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. (Full text)

Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. 26488714 2015 10 27 2018 11 13 1533-4406 373 17 2015 Oct 22 The New England journal of medicine N. Engl. J. Med. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. 1680-2 10.1056/NEJMc1506163 Mammen Andrew L AL National Institutes of Health, Bethesda, MD andrew.mammen@nih.gov. Tiniakou Eleni E eng T32 AR048522 AR NIAMS NIH HHS United States ZIA AR041203-01 NULL Intramural NIH HHS United States T32-AR-048522

2015 NEJM PubMed

129. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444734 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1476-7 10.1056/NEJMc1509363 Cannon Christopher P CP Blazing Michael A MA Braunwald Eugene E eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM PubMed

130. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444735 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1473 10.1056/NEJMc1509363 Silbernagel Günther G Baumgartner Iris I März Winfried W eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM PubMed

131. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444736 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1473-4 10.1056/NEJMc1509363 Couture Philippe P Durand Madeleine M Laskine Mikhael M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM PubMed

132. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444737 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1474 10.1056/NEJMc1509363 Egom Emmanuel E EE eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J Med. 2015 Jun

2015 NEJM PubMed

133. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444738 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1474-5 10.1056/NEJMc1509363 Patti Giuseppe G Cavallari Ilaria I eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J

2015 NEJM PubMed

134. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444739 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1475 10.1056/NEJMc1509363 Nunes José P L JP eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J Med. 2015 Jun 18;372

2015 NEJM PubMed

135. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444740 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1475-6 10.1056/NEJMc1509363 Richard Thibault T Lelubre Christophe C Vanhaeverbeek Michel M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM PubMed

136. Ezetimibe plus a Statin after Acute Coronary Syndromes. (Full text)

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444741 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1476 10.1056/NEJMc1509363 Singh Jagdeep S JS Struthers Allan D AD Lang Chim C CC eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin

2015 NEJM PubMed

137. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines (Full text)

Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults (...) with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear.Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal

2015 EvidenceUpdates PubMed

138. Do statins increase the risk of developing diabetes?

Do statins increase the risk of developing diabetes? Do statins increase the risk of developing diabetes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do statins increase the risk of developing diabetes? View/ Open Date 2015-04 Contributor Format Metadata Abstract Q: Do statins increase the risk of developing (...) diabetes? A: Yes. Statin therapy produces a small increase in the incidence of diabetes: one additional case per 255 patients taking statins over 4 years (strength of recommendation [SOR]: A, meta-analysis). Intensive statin therapy, compared with moderate therapy, produces an additional 2 cases of diabetes per 1000 patient years (SOR: B, meta-analysis with significant heterogeneity among trials). URI Citation Journal of Family Practice, 64(4) 2015: 245-246. Rights OpenAccess. This work is licensed

2015 Clinical Inquiries

139. Do statins increase the risk of developing diabetes?

Do statins increase the risk of developing diabetes? Do statins increase the risk of developing diabetes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do statins increase the risk of developing diabetes? View/ Open Date 2015-04 Contributor Format Metadata Abstract Q: Do statins increase the risk of developing (...) diabetes? A: Yes. Statin therapy produces a small increase in the incidence of diabetes: one additional case per 255 patients taking statins over 4 years (strength of recommendation [SOR]: A, meta-analysis). Intensive statin therapy, compared with moderate therapy, produces an additional 2 cases of diabetes per 1000 patient years (SOR: B, meta-analysis with significant heterogeneity among trials). URI Citation Journal of Family Practice, 64(4) 2015: 245-246. Rights OpenAccess. This work is licensed

2015 Clinical Inquiries

140. Preoperative statin therapy for patients undergoing cardiac surgery. (PubMed)

Preoperative statin therapy for patients undergoing cardiac surgery. Patients referred to cardiac surgery for cardiovascular disease are at significant risk for the development of major postoperative adverse events despite significant advances in surgical techniques and perioperative care. Statins (5-hydroxy-3-methylglutaryl-co-enzyme A (HMG-CoA) reductase inhibitors) have gained a pivotal role in the primary and secondary prevention of coronary artery disease and are thought to improve (...) perioperative outcomes in patients undergoing cardiac surgery. This review is an updated version of a review that was first published in 2012.To determine the effectiveness of preoperative statin therapy in patients undergoing cardiac surgery.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 11), MEDLINE (1950 to November 2013 Week 3), EMBASE (1980 to 3 December 2013 (Week 48)) and the metaRegister of Controlled Trials. Additionally, we searched ongoing trials through

2015 Cochrane